𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pain sensitivity and clinical progression in Parkinson's disease

✍ Scribed by Veit Mylius; Juliane Brebbermann; Helena Dohmann; Isabel Engau; Wolfgang H. Oertel; Jens C. Möller


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
128 KB
Volume
26
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Pain sensitivity in Parkinson's disease is known to be altered in an L‐dopa‐dependent manner with increased spinal nociception and experimental pain perception in the medication‐defined “off” state. As Parkinson's disease‐related pain can be an early symptom in Parkinson's disease, the present study aimed to investigate experimental pain sensitivity and spinal nociception during clinical progression. The nociceptive flexion reflex as a marker of spinal nociception as well as electrical and heat pain thresholds were assessed during the medication‐defined “off” state in 29 patients with Parkinson's disease divided into 3 severity groups (according to their Unified Parkinson's Disease Rating Scale motor score) and compared with 27 healthy elderly subjects. Parkinson's disease‐related pain was also quantified. Data provided evidence that spinal nociception and pain sensitivity are preserved during the early phase of Parkinson's disease. Following increased spinal nociception (F~1,36~ = 6.838, P = .013), experimental thermal and electrical pain sensitivity were augmented during the course of Parkinson's disease (F~1,34~ = 5.397, P = .014; F~1,34~ = 6.038, P = 0.053), whereas spinal nociception further increased (F~1,34~ = 5.397, P < .001). Increased experimental pain sensitivity was observed in patients exhibiting Parkinson's disease‐related pain. Spinal alterations either on the local level or induced by diminished dopaminergic descending inhibition probably led to increased pain sensitivity in later stages. Because Parkinson's disease‐related pain is correlated with experimental pain sensitivity these 2 observations likely reflect a causal relation. © 2011 Movement Disorder Society


📜 SIMILAR VOLUMES


Clinical measures of progression in Park
✍ Werner Poewe 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 1 views

## Abstract Despite all recent advances in symptomatic therapy Parkinson's disease (PD) continues to be a relentlessly progressive neurodegenerative disorder. Therefore therapies that will slow or hold disease progression are a major medical unmet need in PD. Clinical measures of disease progressio

Pain in Parkinson's disease
✍ Ainhi D. Ha; Joseph Jankovic 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

## Abstract Pain and other nonmotor symptoms in PD are increasingly recognized as a major cause of reduced health‐related quality of life. Pain in PD may be categorized into a number of different subtypes, including musculoskeletal, dystonic, radicular neuropathic, and central pain. The onset of pa

Pain in Parkinson's disease
✍ Dr. Christopher G. Goetz; Caroline M. Tanner; Mark Levy; Robert S. Wilson; David 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 371 KB

Summnry: We studied the prevalence and character of pain in Parkinson's disease (PD) and its associatjon with motor fluctuations. Of 95 outpatients, 46% experienced pain they attributed to PD. Patients with pain were younger but no more disabled on objective motor scores than patients without pain.

Pain and dyskinesia in Parkinson's disea
✍ Carlos Juri; Maria C. Rodríguez-Oroz; Juan A. Burguera; Jorge Guridi; Jose A. Ob 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB

Lerner and Bagic 1 have to be congratulated for their hypothesis on PD pathogenesis. They suggest that the sequence of the brain changes in PD follows specific and repeatable patterns in all cases, as well as that a prion-like process underlies neurodegeneration. These ideas could explain several fe

Rate of clinical progression in Parkinso
✍ Anette Schrag; Richard Dodel; Annika Spottke; Bernhard Bornschein; Uwe Siebert; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 1 views

## Abstract Few prospective data on the clinical progression of Parkinson's disease (PD) in patient groups outside treatment trials in selected patients are available, and controversy exists on the rate of clinical disease progression with advancing disease. In this study, we investigated the rate